前收市價 | 0.2500 |
開市 | 0.2500 |
買盤 | 0.0000 |
賣出價 | 0.0000 |
拍板 | 260.00 |
到期日 | 2024-07-19 |
今日波幅 | 0.2500 - 0.2500 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.